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Background: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) 
is an autosomal-dominant autoinflammatory disease caused by mutations in the 
TNFRSF1A gene. R92Q, a low-penetrance variant, is usually associated with a milder 
TRAPS phenotype than structural or pathogenic mutations. No studies differentiating 
R92Q-related disease in patients with pediatric and adult onset have been performed 
to date.
Objective: To analyze clinical features and disease outcomes in patients diagnosed with 
TRAPS associated with R92Q variant and to investigate differences between patients 
with pediatric and adult disease onset.
Methods: A retrospective review of patients with R92Q-related disease from four refer-
ence centers for autoinflammatory diseases was performed. Clinical and laboratory fea-
tures, family history of autoinflammatory diseases, treatments received, and outcomes 
during follow-up were recorded and separately analyzed in pediatric and adult patients. 
Our results were included in the analysis with other reported pediatric and adult R92Q-
related disease series.
results: Our series encompassed 18 patients (9 females and 9 males) with R92Q 
variant. In 61% of patients, disease onset occurred during infancy and in 39%, during 
adulthood, with a median diagnostic delay of 5 years and a follow-up of 5.4 years. A 
positive family history of autoinflammatory disease was detected in 28% of patients. All 
patients presented with febrile recurrent episodes. Other common symptoms included 
arthralgia/arthritis (61%), myalgia (39%), asthenia/fatigue (44%), abdominal pain (39%), 
Abbreviations: TNF, tumor necrosis factor; TRAPS, tumor necrosis factor receptor-associated periodic syndrome.
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inTrODUcTiOn
The term autoinflammatory diseases was first coined in 1999 
by Kastner et  al. to encompass a group of clinical syndromes 
characterized by an increased systemic inflammatory reaction, 
mediated predominantly by cells and molecules of the innate 
immune system, and caused by mutations in genes involved in the 
control of inflammatory pathways (1). Among autoinflammatory 
diseases, tumor necrosis factor receptor-associated periodic syn-
drome (TRAPS; OMIM 142680), described as familial Hibernian 
fever in 1982 (2), was defined as an autosomal-dominant disease 
caused by mutations in the TNFRSF1A gene (located on chromo-
some 12p13) in 1999 (1).
Although classically TRAPS affects mostly children below 
10 years of age, it can also occur in adult patients (3–9). No sex 
dominance has been reported (6–11). Clinical features of TRAPS 
include recurrent fever episodes associated with musculoskeletal 
symptoms, migratory rash, and ocular manifestations (5–14). 
Raised acute phase reactants during attacks are also typical (5, 8, 
10, 11). About 10–15% of patients with TRAPS may develop amy-
loidosis (6–8, 10, 11, 15). Psychological stress, physical exercise, 
infections, menstruation, or vaccinations have been occasionally 
identified as trigger factors of the attacks (5).
Most of the sequence variants identified in TRAPS patients 
are located in the exons 2–4 (see Infevers database in http://fmf.
igh.cnrs.fr/ISSAID/infevers) (16). Those missense substitutions 
disrupting structurally important cysteine–cysteine disulfide 
bonds in the extracellular domain and other mutations, such as 
T50M, are known as structural or pathogenic variants (5, 14). 
Moreover, two frequent variants, R92Q (the common name 
for p.Arg121Gln, located in exon 4) and P46L (also known as 
p.Pro75Leu, located in exon 3), are known by causing a variable 
TRAPS phenotype in some patients. In addition, these mutations 
can be observed in asymptomatic first-degree relatives and in 
healthy individuals (8, 14). For these reasons, R92Q and P46L 
have been recently classified as variants of uncertain significance 
(17). However, the potential pathogenic role of low-penetrance 
mutations causing TRAPS or TRAPS-like phenotypes still gener-
ates controversy among investigators (5, 6, 9, 12, 13).
Several studies have reported that patients carrying R92Q tend 
to present with milder disease phenotype and better long-term 
prognosis compared with those carrying structural or pathogenic 
TNFRSF1A mutations, who usually suffer from more severe 
manifestations and long-term complications (e.g., amyloidosis) 
(4–11, 18). While structural mutations are typically observed in 
children, those patients with adult onset of TRAPS more often 
carry the R92Q variant (4, 8).
Studies focused on R92Q-related disease are scarce. In 
addition, no studies on TRAPS associated with R92Q variant 
(or R92Q-related disease) differentiating disease phenotype, 
treatment requirements, and outcomes according to the age 
at disease onset (pediatric and adult) have been performed to 
date. Therefore, we aimed to investigate clinical and laboratory 
features, therapeutic approaches, and long-term outcomes in a 
cohort of pediatric and adult patients carrying the R92Q low-
penetrance variant in TNFRSF1A gene, with special interest in 
the analysis of differences between the two age groups. Previous 
pediatric and adult case series of patients with R92Q-related 
disease reported in the literature were also reviewed and used for 
final comparisons.
MaTerials anD MeThODs
Patients’ selection and Data collection
From January 2006 to June 2016, we retrospectively reviewed 
medical charts of pediatric and adult patients diagnosed with 
an autoinflammatory disease attributed to R92Q variant in 
TNFRSF1A gene, in four reference centers for autoinflamma-
tory diseases (Clinical Unit of Autoinflammatory Diseases, 
Departments of Autoimmune Diseases and Immunology, 
Hospital Clínic of Barcelona, Barcelona, Spain; Pediatric 
headache (33%), odynophagia (33%), skin rash (28%), and chest pain (22%). During 
attacks, 80% of patients increased acute phase reactants levels. No patient had devel-
oped amyloidosis during the study period. At the end of follow-up, 28% of patients were 
asymptomatic and treatment free, 50% were receiving non-steroidal anti-inflammatory 
drugs or glucocorticoids on demand, and 22% were being treated with biologic agents. 
When differences between pediatric and adult patients were globally analyzed, adults 
tended to have longer attacks duration and presented more frequently with chest pain 
and headache, while abdominal pain, vomiting, cervical adenitis, and pharyngitis pre-
dominated in pediatric patients. No differences in outcomes and treatment requirements 
were observed in both age groups.
conclusion: This study has contributed to characterize R92Q-related disease by iden-
tifying trends in disease phenotypes depending on the age at disease onset.
Keywords: tumor necrosis factor receptor-associated periodic syndrome, r92Q, low-penetrance variants, 
autoinflammatory diseases, pediatric onset, adult onset
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Rheumatology Unit, Department of Pediatrics, Hospital Sant 
Joan de Déu, Barcelona, Spain; Rheumatology Unit, Department 
of Internal Medicine, Arcispedale Santa Maria Nuova – IRCCS, 
Reggio Emilia, Italy; and Autoimmune and Systemic Diseases 
Unit, Department of Internal Medicine, Hospital Vall d’Hebron, 
Barcelona, Spain).
Patients were included if an autoinflammatory disease was 
suspected after ruling out autoimmune, infectious, or malignant 
causes, and R92Q low-penetrance variant in TNFRSF1A gene was 
found. Patients with structural variants in TNFRSF1A gene or 
with concomitant mutations in MEFV, MVK, and NLRP3 genes 
were excluded to avoid potential confounding factors for a more 
accurate diagnosis.
The recently published provisional Eurofever classification 
criteria for autoinflammatory diseases (9) were used to assess 
the level of agreement with TRAPS diagnosis in our patients. 
Variables (and their values) for TRAPS classification included: 
duration of episodes more than 6 days (19 points), presence of 
periorbital edema (21 points) or migratory rash (18 points), and 
also absence of vomiting (14 points) or oral aphthae (15 points). 
In patients with structural mutations, a cut-off value ≥43 was 
reported to yield 80% sensitivity and 91% specificity for TRAPS 
classification (9). Of note, in the same study, these criteria were 
associated with lower sensitivity and specificity (59 and 84%, 
respectively) for patients carrying the R92Q variant, although 
52% of them could be still classified as TRAPS (9).
Clinical features recorded included frequency and duration 
of attacks, and presence of fever, arthralgia/arthritis, myalgia, 
abdominal and chest pain, cutaneous rash, ocular symptoms, and 
other less frequent manifestations (Table 1). Type of medications 
used and response to them, at disease onset and during follow-up, 
as well as their continuous or on-demand administration, were 
also collected. Laboratory parameters included complete blood 
cell counts, C-reactive protein (CRP) and/or serum amyloid A 
(SAA) levels, erythrocyte sedimentation rate (ESR), urinalysis 
with proteinuria, and markers of autoimmunity, such as anti-
nuclear antibodies, rheumatoid factor, and complement levels. 
Genetic testing of the most common genes causing monogenic 
autoinflammatory diseases (TNFRSF1A for TRAPS, MEFV for 
familial Mediterranean fever, MVK for mevalonate kinase defi-
ciency, and NLRP3 for cryopyrin-associated periodic syndromes) 
was carried out.
This retrospective study was approved by the Research Ethics 
Committee of the Hospital Clínic of Barcelona. Patients’ informa-
tion was dissociated prior to analysis, and all procedures were 
performed in accordance with the ethical principles expressed in 
the 2013 Declaration of Helsinki.
groups Based on age at Disease Onset 
and review of the literature
Based on previous studies, patients aged <16 and ≥16 years at 
disease onset were considered to have pediatric and adult disease 
onset, respectively (4, 11, 13). In addition, those cohort series of 
patients with R92Q-related disease reported until 2016 (identi-
fied through PubMed search) with consistent data about clinical 
manifestations and outcomes during the follow-up, which also 
provided separate information with regard to the age of disease 
onset (pediatric and adult), were compared with our case series 
and used for global calculations.
statistical analysis
Results (in text and tables) are expressed as mean ± SD or median 
plus range, where applicable. Chi-square or Fisher’s exact tests 
were used for contingency tables. Quantitative differences 
between groups were analyzed by using Student’s unpaired t-test. 
Data were analyzed with the SPSS PC statistical package (ver-
sion 20.0). Differences with a value of p < 0.05 were considered 
statistically significant.
resUlTs
Overall characteristics of Patients of all 
ages with r92Q-related Disease
A total of 18 patients with R92Q variant in TNFRSF1A gene follow-
ing inclusion criteria were analyzed. Seven patients were excluded 
because of carrying the R92Q variant and other concomitant 
mutations in NLRP3 and MEFV genes, or they presented with a 
disease phenotype permitting a different definite diagnosis. None 
of the included patients met diagnostic criteria for periodic fever, 
aphthous stomatitis, pharyngitis, and adenitis syndrome (19).
When provisional Eurofever classification criteria for TRAPS 
(9) were applied in our patients, 10 (56%) of them reached the 
cut-off for TRAPS classification. Among these, four (36%) were 
children and six (86%) adult patients (p = 0.066).
Nine (50%) patients were female and nine (50%) were male. 
In 11 (61%) patients, disease onset occurred during infancy, at a 
mean age of 7.6 years (median 8 years; range 1–15 years); and in 
seven (39%) patients, symptoms started during adulthood, at a 
mean age of 25 years (median 23 years; range 16–43 years). Seven 
(39%) and 11 (61%) patients were diagnosed during pediatric and 
adult age, respectively. Overall, mean diagnostic delay was 5 years 
(median 3 years; range 4 months–25 years).
All patients presented with febrile recurrent episodes with 
disease-free intervals. A remarkable intersubject and intrasubject 
variability was observed with regard to duration and frequency 
of attacks (Table 1). The most common symptoms accompanying 
fever episodes were arthralgia/arthritis (61%), myalgia (39%), 
asthenia/fatigue (44%), abdominal pain (39%), headache (33%), 
odynophagia (33%), skin rash (29%), and chest pain (22%). Other 
less frequent manifestations included facial/periocular edema, 
oral aphthae, cervical adenitis, and conjunctivitis. A positive 
family history of an autoinflammatory (R92Q-related) disease 
was detected in five (28%) patients (four children and one adult).
During attacks, 80% of patients had increased CRP or SAA 
levels and 50% of them showed high ESR values. However, hemo-
globin levels and leukocyte and platelet counts were abnormal in 
less than half of patients during attacks. At the end of follow-up, 
proteinuria or other AA amyloidosis signs were not observed in 
any of our patients. With regard to genetic results, all patients 
included in the study carried R92Q low-penetrance variant in 
TNFRSF1A gene (16 of them as heterozygous mutations and 
two in homozygosity), and no other mutations were identified in 
MEFV (17 patients), MVK (16 patients), or NLRP3 (14 patients) 
genes.
TaBle 1 | Demographic, clinical, and laboratory features of patients with r92Q variant in our study series.
a B c p Value (a vs. B)
r92Q patients with pediatric 
onset (n = 11)
r92Q patients with adult 
onset (n = 7)
all r92Q patients (n = 18)
Demographic data
Sex (female/male) 4/7 5/2 9/9 0.34
Age at symptoms onset (years) 7.6; 8 (1–15) 25; 23 (16–43) 14.3; 12 (1–43) 0.004
Age at diagnosis (years) 12; 12 (5–16) 31; 25 (16–48) 19; 16 (5–48) 0.015
Time from disease onset to diagnosis (years) 4.1; 4 (0.3–9) 5.8; 2 (0.3–25) 5; 3 (0.3–25) 0.65
Follow-up (years) 6.2; 6 (2–10) 4; 5 (1–8) 5.4; 5.5 (1–10) 0.18
Positive family history 4 (36) 1 (14) 5 (28) 0.60
TRAPS Eurofever classification criteriaa 4 (36) 6 (86) 10 (56) 0.066
clinical featuresb
Fever (≥38°C) 11 (100) 7 (100) 17 (100) 1
Asthenia/fatigue 6 (55) 2 (29) 8 (44) 0.37
Arthralgia/arthritis 6 (55) 5 (71) 11 (61) 0.64
Myalgia 4 (36) 3 (43) 7 (39) 1
Abdominal pain 5 (46) 2 (29) 7 (39) 0.63
Vomiting 1 (9) 0 (0) 1 (6) 1
Chest (pleuro-pericardial) pain 1 (9) 3 (43) 4 (22) 0.25
Skin rash 2 (18) 3 (43) 5 (28) 0.33
Headache 3 (27) 3 (43) 6 (33) 0.63
Conjunctivitis 2 (18) 1 (14) 3 (17) 1
Periorbital edema 1 (9) 1 (14) 2 (11) 1
Cervical adenitis 3 (27) 0 (0) 3 (17) 0.25
Pharyngitis/odynophagia 4 (36) 2 (29) 6 (33) 1
Oral aphthae 2 (18) 1 (14) 3 (17) 1
attacks characteristicsc
Duration (days) 22; 4 (2–160) 35; 21 (4–90) 27; 11 (2–160) 0.056
Frequency (per year) 12; 6 (1.5–50) 5; 6 (0.3–8) 9; 6 (0.3–50) 0.20
laboratory (during attacks)d
CRP >1.5 mg/dL and/or SAA >6.4 mg/dL 6/8 (75) 6/7 (86) 12/15 (80) 1
ESR >20 mm first hour 4/8 (50) 2/4 (50) 6/12 (50) 1
Leukocyte count >11,000/mm3 3/8 (38) 2/5 (40) 5/13 (38) 1
Hemoglobin <120 mg/L 2/8 (25) 0/5 (0) 2/13 (15) 0.5
Platelets count >350,000/mm3 0/7 (0) 2/5 (40) 2/12 (17) 0.15
Proteinuria (absence) at the end of follow-up 10/10 (100) 6/6 (100) 15/15 (100) 1
Other studied genes (negative/performed)
MEFV 11/11 (100) 6/6 (100) 17/17 (100) 1
MVK 9/9 (100) 7/7 (100) 16/16 (100) 1
NLRP3 8/8 (100) 6/6 (100) 14/14 (100) 1
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MEFV, Mediterranean fever gene; MVK, mevalonate kinase gene; NLRP3, nod-like receptor family pyrin domain 
containing 3 gene; TRAPS, tumor necrosis factor receptor-associated periodic syndrome.
Continuous values are given as mean; median (range).
aPatients achieving provisional Eurofever classification criteria for TRAPS (9).
bValues as total number of patients and %.
cBecause a remarkable intrasubject variability with regard to duration and frequency of attacks was found in the majority of patients, only the highest values were used for 
calculations.
dAbnormal values during attacks, later normalized (from available results).
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The main demographic, clinical, and laboratory features of 
all patients with R92Q variant from our patients are depicted in 
Table 1. Data from the main (all retrospective) series with mixed 
pediatric and adult results published to date are shown in Table 2.
Global results from series with patients of all ages with R92Q-
related disease (5, 8–10, 12), including ours, confirmed no sex 
preference and a family history of an autoinflammatory (R92Q-
related) disease was recorded in 7–28% of cases (5, 8, 12). The age 
at disease onset ranged from less than 1 year to the fourth to sixth 
decades. The mean/median of attacks duration varied between 
4.7 and 16 days (8, 10, 12) and the frequency of attacks between 6 
and 11 episodes per year (10) (with marked inter- and intra-study 
variability for both parameters). Fever was present in almost 100% 
of patients (5, 9, 10, 12), except in one study that showed lower 
prevalence (8). Arthralgia/arthritis was present in about half to 
two-thirds of patients, myalgia in 39–66%, abdominal pain in 
39–66% (5, 8–10, 12), vomiting in 6–40% (5, 9, 12), chest/pleuro-
pericardial pain in 22–33%, skin rash in 20–36%, headache in 
16–53%, conjunctivitis in 6–20%, periorbital edema in 7–19%, 
cervical adenitis or lymphadenopathy in 17–26%, odynophagia 
or pharyngitis in 12–33%, and oral aphthosis in 14–40% of cases 
(5, 8–10, 12). Of note, the study by Hull et  al. (10) reported a 
higher frequency of joint, muscular, skin, and ocular involvement 
than the other studies (Table 2). Between 80 and 100% of patients 
TaBle 2 | Demographic, clinical, and laboratory features of the main series combining adult and pediatric patients with r92Q-related disease.
hull et al. 
(10)
ravet et al. (8) gattorno 
et al. (12)b
lachmann et al. (5)c Federici 
et al. (9)d
ruiz-Ortiz et al.  
(present series)
Demographic data
N 9 34 15 54 78 18
Sex (female/male) 3/6 17/17 – – 38/40 9/9
Age at symptoms onset (years)a 22 (<1–53) 19 58 ± 64 6 (0–53) 6 (3–19) 12 (1–43)
Age at diagnosis (years)a – – – – – 16 (5–48)
Time from disease onset to diagnosis (years)a – – – – 6.4 
(3.4–25.9)
3 (0.3–25)
Follow-up (years)a – – – – 13 5.5 (1–10)
Positive family history (%) – 21 7 19 – 28
clinical features (%)
Fever (≥38°C) 100 48 100 94 100 100
Asthenia/fatigue – – – – 72 44
Arthralgia/arthritis 89 48 17 66 65 61
Myalgia 89 48 53 66 28 39
Abdominal pain 56 39 60 66 59 39
Vomiting – – 40 26 26 6
Chest (pleuro-pericardial) pain 33 32 13 22 24 22
Skin rash 78 36 33 30 20 28
Headache – 16 53 39 5 33
Conjunctivitis 100 6 13 17 20 17
Periorbital edema 78 12 7 17 19 11
Cervical adenitis/lymphadenopathy – 19 60 25 26 17
Pharyngitis/odynophagia – 12 67 24 22 33
Oral aphthae – – 40 14 15 17
attacks characteristics
Duration (days) 16 (6–30) 7.4 4.7 ± 3.7 – – 11 (2–160)
Frequency (per year) 11 (9–>12) – – – – 6 (0.3–50)
increased inflammatory markers during 
attacks (%)
100 100 – – – 80
Other studied genes (negative/performed) – MEFV (some 
positive)
MEFV, MVK MEFV (22/22), MVK 
(11/11), NLRP3 (2/2)
– MEFV (17/17), MVK (16/16), 
NLRP3 (14/14)
amyloidosis development (%) 0 6.2 – 0 – 0
aContinuous results as mean or median, plus SD or range (when available).
bData from 15 patients with TNFRSF1A low-penetrance variants; among them, 13 (87%) patients carried R92Q (12).
cData from 59 patients with TNFRSF1A P46L and R92Q variants; among them, 54 (91.5%) patients carried R92Q (5).
dData from 78 patients with TNFRSF1A low-penetrance mutations, no mutations or genetic test not done or P46L and R92Q variants; among them, 57 (73%) patients carried R92Q (9).
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had elevated acute phase reactants (mainly CRP and/or SAA) 
during attacks (8, 10). Overall, results from our study group did 
not differ with those from the previously reported series.
Differences between Patients with 
Pediatric and adult Onset of r92Q-
related Disease
No statistically significant differences with regard to clinical and 
laboratory features at disease presentation were found in the 
present series between pediatric and adult patients (Table  1). 
However, when previous studies on R92Q-related disease 
including patients with pediatric (7, 11, 13) and adult onset 
(6, 7) were analyzed together with our results (Table 3), no sex 
predominance was observed and a positive family history of 
R92Q-related disease tended to be higher in pediatric (4–50%) 
than in adult patients (6–17%). The mean/median age at disease 
onset was of 3.6–8 years in children and 23–28.8 years in adults. 
Duration of attacks tended to be longer in adult patients (mean/
median from 7 to 21 days) than in children (from 4 to 9 days). 
Frequency of attacks was similarly heterogeneous in both groups. 
Among clinical features, fever was equally present in almost all 
patients, in all studies. Arthralgia/arthritis, myalgia, skin rash, 
ocular symptoms, and oral aphthae occurred in a similar pro-
portion in both groups. Chest pain was consistently reported in 
almost half of adult patients and less frequently in most pediatric 
studies. Headache was also observed in a higher proportion in 
adults (42–43%) than in children (20–30%). Conversely, abdomi-
nal pain was more often presented by children (40–67%) than 
by adults (25–33%). Vomiting was not reported in adult series 
but occurred in 9–30% of pediatric patients. Cervical adenitis 
or lymphadenopathy (27–65 vs. 0–19%) and pharyngitis or 
odynophagia (13–65 vs. 11–29%) were predominantly observed 
in children (6, 7, 11, 13).
Disease Outcomes and Therapeutic 
approaches during Disease course
Patients in our study were followed for a mean of 5.4 years (median 
5.5 years; range 1–10 years). Only two recent studies have also 
reported information from patients with R92Q-related disease 
after a long-term follow-up period (6, 11) (Table 3). Therapeutic 
strategies in ours and those previous studies similarly included 
the use of non-steroidal anti-inflammatory drugs (NSAIDs), 
TaBle 3 | characteristics of patients with r92Q low-penetrance TNFRSF1A variants in studies including patients with pediatric and adult onset.
Pediatric-onset series adult-onset series
Dodé et al. 
(7)
lainka 
et al. (13)b
Pelagatti et al. 
(11)
ruiz-Ortiz 
et al. 
(present 
series)
Dodé et al. 
(7)
cantarini et al. 
(6)c
ruiz-Ortiz 
et al. 
(present 
series)
Demographic data
Patients (N) 6 15 20 11 6 25 7
Sex (female/male) 3/3 – 9/11 4/7 1/5 17/19 5/2
Age at symptoms onset (years)a 7.3 (2–15) 5 (1–14) 3.6 (0.6–13) 8 (1–15) 28.8 (22–36) 26.6 ± 15 23 (16–43)
Age at diagnosis (years)a – 7 (1–16) 6.1 (1.2–15) 12 (5–16) – – 25 (16–48)
Time from disease onset to diagnosis (years)a – – – 4 (0.3–9) – – 2 (0.3–25)
Follow-up (years)a – – 7.3 (1.7–14.3) 6 (2–10) – 12.7 ± 11.3 5 (1–8)
Positive family history (%) 50 – 4 36 17 6 14
clinical features (%)
Fever (≥38°C) 100 100 100 100 100 97 100
Asthenia/fatigue – – – 55 – – 29
Arthralgia/arthritis 17 53 40 55 17 55 71
Myalgia – 27 35 36 – 55 43
Abdominal pain 67 40 40 46 33 25 29
Vomiting – 20 30 9 – – 0
Chest (pleuro-pericardial) pain 50 20 4 9 50 50 43
Skin rash 50 33 20 18 17 19 43
Headache – 20 30 27 – 42 43
Conjunctivitis – 13 10 18 – 19d 14
Periorbital edema – – 0 9 – 19d 14
Cervical adenitis/lymphadenopathy – 40 65 27 – 19 0
Pharyngitis/odynophagia – 13 65 36 – 11 29
Oral aphthae – – 35 18 – 25 14
attacks characteristics
Duration (days) 6 (1–20) 9 (2–24) 5.9 (3–15) 4 (2–160) 7.5 (2–20) >7 (69%) 21 (4–90)
Frequency (per year) 20 (6–30) – 10.3 (3–20) 6 (1.5–50) 27.6 (6–48) 7 ± 3.9 6 (0.3–8)
increased inflammatory markers during 
attacks (%)
– 100 100 75 – 100e 86
Other studied genes (negative) MEFV MEFV, MVK MEFV, MVK MEFV, MVK, 
NLRP3
MEFV MEFV, MVK, 
NLRP3, NLRP12
MEFV, MVK, 
NLRP3
amyloidosis development (%) 17 – 0 0 0 0 0
aContinuous results as mean or median, plus SD or range (when available).
bData obtained from 15 patients with R92Q variants in TNFRSF1A gene (13).
cData from 36 patients with TNFRSF1A low-penetrance variants; among them, 25 (69%) patients carried R92Q (6).
dOverall value for ophthalmological abnormalities (which included the presence of conjunctivitis and/or periorbital edema) in this series was 19%.
eAll patients had high serum amyloid A values but normal C-reactive protein levels.
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colchicine, oral glucocorticoids (usually at a dose equivalent to 
≥0.5  mg/kg/day of prednisone), and biologic agents (anakinra 
and etanercept, as IL-1 and TNF blockers, respectively).
Medications used in our cohort are illustrated in Table 4. As 
starting treatment, NSAIDs on demand were used in 6 patients, 
colchicine in 2 patients, glucocorticoids in 11 patients (5 with 
continuous and 6 with on-demand administration), and etaner-
cept and anakinra, in 1 and 2 patients, respectively. At the end of 
follow-up, five (28%) patients were asymptomatic and treatment 
free (representing 18% of pediatric and 43% of adult patients), 
five (28%; 36% of pediatric and 14% of adult patients) continued 
receiving on-demand NSAIDs, four (22%; 27% of pediatric and 
14% of adult patients) were on glucocorticoids on demand, and 
four (22%; 18% of pediatric and 28% of adult patients) were 
treated with biologic agents (one with weekly etanercept, and 
two and one with anakinra, daily and on demand, respectively).
Previous data on disease outcomes and treatment used at 
the end of follow-up in a series of pediatric patients with R92Q-
related disease revealed that 25% of cases had shown spontaneous 
resolution of symptoms, 12 and 44% were being treated with 
NSAIDs and glucocorticoids on demand, respectively, and 18% 
with continuous glucocorticoids or biologic agents (11). In a 
previous adult series, at the end of the study, about 8% of cases 
were receiving only NSAIDs, 46% glucocorticoids on demand, 
23% continuous glucocorticoids, 3% colchicine, and 19% were 
being treated with cytokine blockers (6).
Although these studies analyzed small number of patients, all 
of them showed similar trends regarding disease outcomes and 
therapeutic strategies utilized, without clear differences between 
pediatric and adult patients.
DiscUssiOn
R92Q has been recently classified by a panel of expert clini-
cians and geneticists in autoinflammatory diseases as a variant 
of uncertain significance because its common presence in the 
general population and by the fact that this variant does not 
segregate with the phenotype in members of the same family 
TaBle 4 | Treatment characteristics at baseline and at the end of 
follow-up.
r92Q patients 
with pediatric 
onset (n = 11)
r92Q patients 
with adult onset 
(n = 7)
all r92Q 
patients (n = 18)
initial treatment
NSAIDs 3 (OD) 3 (OD) 6 (OD)
Colchicine 1 (C) 1 (C)c,d 2 (C)
Glucocorticoids 5 (OD); 2 (C)a,b 1 (OD); 3 (C)c,d,e 6 (OD); 5 (C)
Biological agents 1 AN (C)a; 1 ET (C)b 1 ET/AN (C)d 1 AN (C); 1 ET (C); 
1 ET/AN (C)
Treatment at the end of follow-up
No treatment 2 3 5
NSAIDs 4 (OD) 1 (OD) 5 (OD)
Colchicine 0 0 0
Glucocorticoids 3 (OD) 1 (OD) 4 (OD)
Biological agents 1 AN (OD)a;  
1 ET (C)b
1 AN (OD)d;  
1 AN (C)e
3 AN (2 OD, 1 C); 
1 ET (C)
AN, anakinra; C, continuous; ET, etanercept; OD, on demand; NSAIDs, non-steroidal 
anti-inflammatory drugs.
Patients a and b initially received glucocorticoids and a biological agent; and at the end 
of follow-up, patient a is receiving anakinra on demand and patient b, etanercept 50 mg/
week. Patient c received colchicine and glucocorticoid therapy. Patient d was treated 
with colchicine, prednisone, etanercept, and finally, anakinra (on an initial continuous 
administration, which could be switched to on demand during the disease course). 
Patient e started with continuous glucocorticoids and was later switched to anakinra.
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(17). Compared to patients with TNFRSF1A structural or patho-
genic mutations, patients carrying the R92Q variant exhibit 
milder disease presentation and disease outcome, shorter febrile 
episodes, lower intensity and frequency of typical symptoms, a 
considerably lower or inexistent risk for developing amyloidosis, 
and a later (even during adulthood) disease onset (4, 6, 8, 10, 11, 
14). Despite of this milder phenotype, almost all patients with 
R92Q variant are usually treated with (on demand or continuous) 
NSAIDs or glucocorticoids, and a remarkable proportion (up to 
20%) of them may also require biologic therapy (4, 6, 11, 13). In 
addition, R92Q variant has been found in a higher proportion of 
patients with autoinflammatory symptoms than in several control 
populations (6, 7, 13–15). For these reasons, many expert clini-
cians still consider R92Q a low-penetrance mutation rather than 
a polymorphism (4, 6–8, 10, 12–15).
Definite diagnosis of TRAPS usually relies on the presence of 
suggestive clinical features supported by the existence of func-
tional mutations in the TNFRSF1A gene. In this regard, the recent 
TRAPS provisional Eurofever classification criteria for patients 
with structural or pathogenic mutations yielded reasonable 
sensitivity and specificity (9). The same validation study showed 
a remarkable lower sensitivity and specificity for patients carrying 
the R92Q variant, but at least 52% of R92Q patients reached the 
cut-off for TRAPS classification (9). Similarly, 56% of our patients 
with R92Q-related disease could be also classified as having 
TRAPS. Interestingly, this proportion was considerably higher 
for our adult patients (86%) and lower for our children (30%). 
The good concordance with the original TRAPS validation study 
for our patients carrying R92Q makes our results reliable, par-
ticularly for those patients with adult disease onset.
Clinical and laboratory features from previous series includ-
ing R92Q patients of all ages (5, 8–10, 12) are equivalent to those 
found in our series. When patients with R92Q-related disease 
are compared with those carrying structural TNFRSF1A muta-
tions, a family history of an autoinflammatory (R92Q-related) 
disease and the presence of myalgia, abdominal pain, and ocular 
symptoms are more frequently observed in the group with struc-
tural variants, and pharyngitis/odynophagia and oral aphthosis 
predominate in patients with R92Q variant (5, 9). The remaining 
symptoms are similarly presented by patients with structural and 
R92Q variants (5, 9). While a variable proportion of patients 
carrying structural variants may develop amyloidosis over time, 
those carrying R92Q are at a very low (or absent) risk for develop-
ing this complication (5).
When patients with R92Q-related disease with onset dur-
ing childhood (7, 11, 13) are compared with those initiating 
symptoms during adulthood (6, 7), a positive family history of 
an autoinflammatory disease seems to predominate in pediatric 
patients. No sex dominance exists. Although the age at disease 
onset shows wide dispersion, most children usually present with 
disease-related symptoms at 3–7 years of age, and among adults, 
symptoms often start during the second decade of life. Duration 
of attacks seems to be longer in adults, but heterogeneity in dura-
tion and frequency of attacks is equally observed in both groups. 
With regard to clinical manifestations, fever is shared by almost 
all patients; and musculoskeletal, cutaneous, and ocular symp-
toms are common features similarly present in both age groups; 
oral aphthosis occurs in a lower proportion, with no differences 
between children and adults. However, pleuro-pericardial/chest 
pain and headache are more frequently observed in adult patients 
than in children. Conversely, other features, such as abdominal 
pain, vomiting, cervical adenitis/lymphadenopathy, and pharyn-
gitis/odynophagia, seem to be predominant in pediatric patients 
(6, 7, 11, 13).
Although no treatment guidelines for autoinflammatory 
diseases have been elaborated yet, therapeutic approaches for all 
these conditions aim to control symptoms and prevent attacks 
and long-term complications. Previous investigations have docu-
mented differences in disease outcomes and treatments used in 
TRAPS patients carrying structural variants compared to those 
carrying R92Q (or other low-penetrance mutations) (6, 11). 
While patients with structural mutations usually have a chronic 
and relapsing course, with an increased risk for developing amy-
loidosis, and the majority of them also require biologic therapy 
(mainly IL-1 and TNF blockers) (6, 11), most patients with R92Q-
related disease can be treated with NSAIDs or glucocorticoids on 
demand only (6, 11), and in about 25% of patients (pediatric and 
adults), symptoms may evolve to spontaneous resolution during 
the course of the disease, without requiring any treatment (11). 
However, continuous or on-demand administration of biologic 
agents can be indicated in about 20% of cases (6, 11).
The molecular mechanisms responsible for clinical pheno-
types of TRAPS and the role of structural or pathogenic muta-
tions and those low-penetrance variants, such as R92Q, still 
remain to be completely elucidated. While forms of TNFRSF1A 
cysteine mutations clearly destabilize the protein structure and 
produce defects in cell surface expression and TNF binding, 
R92Q mutants, which share structural similarities with the 
wild-type protein, also share similar mechanisms of action with 
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wild-type TNFRSF1A (20). In this sense, structural mutations 
have also shown to produce deeper disturbances in T-cell 
function than R92Q and other low-penetrance variants (21). 
However, recent investigations have demonstrated a constitu-
tive activity of R92Q mutants associated with TRAPS, which 
might be explained by configurational changes induced after 
ligand binding that can act as the trigger for TNFR1 signaling. 
Indeed, these structural changes are not present in wild-type 
receptors (22). Other data, in patients with multiple sclerosis, 
point toward the enhancement of the interaction between the 
receptor and its ligand by the R92Q variant, resulting in the 
potentiation of TNF-mediated pathways (23). In addition, sev-
eral authors have postulated a potential role of low-penetrance 
TNFRSF1A variants (including R92Q, P46L, and other recently 
reported, such as V95M, D12E, and R104Q) in causing different 
autoinflammatory phenotypes (6, 21). These low-penetrance 
variants might also contribute, as a possible susceptibility factor 
in the development of multifactorial polygenic inflammatory 
or autoimmune conditions, such as idiopathic recurrent acute 
pericarditis, Behçet’s disease, juvenile idiopathic arthritis, and 
other autoinflammatory diseases (6, 14, 24–27).
This study has several limitations that include (a) the present 
study and all the previous series on TRAPS and R92Q-related 
disease published to date are retrospective and included a 
relatively small number of patients; (b) very few of them dif-
ferentiated patients with pediatric or adult disease onset; (c) 
most TRAPS series studied patients with R92Q together with 
other low-penetrance variants, thus providing mixed results; (d) 
the small number of patients analyzed, and the heterogeneity in 
some variables and results, make comparisons mainly estima-
tive between patients carrying structural and low-penetrance 
mutations and between R92Q carriers of different ages; and 
(e) pharmacological treatments used in all the studies were 
guided by personal experience, and since no evidence-based 
therapeutic protocols have been elaborated yet, no strong 
recommendations can be made in this regard. However, we 
consider that the present study also has several strengths: (a) 
our results were in concordance with general R92Q-related 
disease series including patients of all ages, and with those 
studies focused in patients with pediatric and adult onset; (b) 
our R92Q patients achieved criteria for TRAPS classification 
in a similar proportion than the R92Q patients included in 
the original Eurofever validation study (9), which was also 
comparable with TRAPS caused by structural mutations for 
our adult patients with R92Q variant.
In summary, this study has contributed to characterize TRAPS 
associated with R92Q variant, particularly in differentiating 
clinical phenotypes according to the age at disease onset. Adult 
patients tend to have longer duration of attacks and exhibit more 
frequently chest pain and headache, than pediatric patients. 
Abdominal pain, vomiting, cervical adenitis/lymphadenopathy, 
pharyngitis/odynophagia, and a family history of an autoinflam-
matory disease seem to predominate in pediatric patients. With 
independence of the age at disease onset, most patients with 
R92Q-related disease usually receive on demand NSAIDs and 
glucocorticoids, and about a quarter part of them may have a 
resolution of symptoms over time, without requiring treatment. 
However, up to 20% of patients may still need biologic agents 
(IL-1 or TNF blockers) at the end of follow-up to control disease 
activity.
The present results evidence the level of clinical and genetic 
complexity of TRAPS phenotype caused by the R92Q variant 
and also lead to emphasize the core importance of interpreting 
genetic results in an appropriate clinical context. In order to cor-
roborate these findings and to achieve a better understanding of 
TRAPS spectrum, further studies including a large number of 
patients with TRAPS, caused by structural mutations, and also 
by R92Q and other low-penetrance TNFRSF1A variants, are 
granted. In addition, whether or not this subset of patients should 
undergo whole exome sequencing to search for concomitant 
disease-causing mutations in unknown genes may be a matter 
of discussion.
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